Neonatal polycythaemia: critical review and a consensus statement of the Israeli Neonatology Association

Abstract

Current definition and management of NP are little evidence based, thus the need for a consensus based on expert opinion.

Polycythemia in neonatal intensive care unit, risk factors, symptoms, pattern, and management controversy

“…Although PET improves cerebral blood flow and hemodynamic parameters in infants with hyperviscosity, there is no evidence that the procedure improves long-term outcome of these infants, and it may be associated with NEC. [2425] The optimal management of PC infants with or without symptoms has not been established and varies among providers, the choices between observations or aggressive hydration is still controversial. The aim of reducing hct in PC infant in our study is to reduce blood viscosity in a symptomatic patient, and to provide early discharge from NICU for asymptomatic PC neonates.…”

Can middle cerebral artery peak systolic velocity predict polycythemia in monochorionic–diamniotic twins? Evidence from a prospective cohort study

“…In cases of in‐vitro fertilization, gestational age was determined according to the date of embryo transfer. Polycythemia was defined as venous hematocrit > 65%, and anemia as hematocrit < 45%. Diagnosis of TAPS was based on the postnatal criteria of an intertwin hemoglobin difference of > 8 g/dL and elevated reticulocyte count in the anemic twin.…”

Review of the correlation between blood flow velocity and polycythemia in the fetus, neonate and adult: appropriate diagnostic levels need to be determined for twin anemia-polycythemia sequence

“…Neonatal diagnosis is made by confirmation of intertwin hemoglobin discordance along with donor reticulocytosis. While no clear clinical definition exists for polycythemia in the fetus, in the neonate it is empirically defined as a venous hematocrit of > 65%. The use of MCA‐PSV for the diagnosis of anemia in singleton pregnancies is well established, with Mari et al reporting a sensitivity of 100% (95% CI, 86–100%) for MCA‐PSV > 1.5 multiples of the median (MoM) in the detection of fetal anemia.…”